SSG Capital Advisors acted as the investment banker to Thousand Oaks Holding Company on the sale of substantially all of the assets of Aerosol Science Laboratories, Sinutopic d/b/a Sinus Dynamics and Topical Apothecary Group to Imprimis Pharmaceuticals. The transaction closed in October 2015.

ASL, SD and TAG are specialty pharmacies focused on compounded medications and proprietary delivery options for the treatment of sinus conditions including allergies, sinusitis and rhinitis. The company’s pharmacists work closely with prescribers to provide effective Topical Sinus Therapy to more than 38,000 patients annually across the U.S. The pharmacies are considered national leaders in the area of TST for their time-tested formulary and clinical pharmacist support for both physicians and patients.

In May 2015, in response to tightening liquidity from declining revenue due to increased regulatory oversight of compounding pharmacies and pressure on insurance reimbursements in the industry, the company consolidated its operations and retained SSG to evaluate strategic alternatives. SSG conducted a comprehensive marketing process to a wide universe of strategic and financial buyers to determine interest in the business as a going-concern. Several parties engaged in a thorough review of the business and submitted offers for all or part of the assets. The offer from Imprimis Pharmaceuticals, a San Diego, CA-based pharmaceutical company, was determined to be the highest and best offer.

Imprimis Pharmaceuticals focuses on utilizing compounding pharmacies for the formulation and distribution of high quality, proprietary formulations that are supported by the clinical experience of physicians and their patients. SSG’s experience in identifying buyers and running a thorough sale process enabled key stakeholders to maximize value by selling the Company to an experienced strategic party with the resources to preserve this effective therapy and serve patients.